This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In their interesting report, Nieuwkerk and colleagues¹ confirm that adherence to highly active antiretroviral therapy (HAART) is limited in patients with human immunodeficiency virus type 1 (HIV-1) infection. The results of their study conducted in the Netherlands are not different from those reported from other countries^2-5 and outline the well-known difficulties in adhering to a complex treatment that requires not only the accurate timing of doses, but also the observance of precise dietary instructions. However, is the patient's full adherence to HAART really vital to avoid disease progression? We believe that the time has come to reconsider the 2 major present "dogmas" in HIV-1 treatment, ie, the necessity of starting therapy using a HAART regimen in all infected subjects, independent of their clinical status, initial viremia, or CD4 cell count, and the importance of doing so to limit the risk of viral resistance due to incomplete suppression of viremia.⁶

We . . . [Full Text of this Article]

RELATED ARTICLE

Limited Patient Adherence to Highly Active Antiretroviral Therapy for HIV-1 Infection in an Observational Cohort Study
Pythia T. Nieuwkerk, Mirjam A. G. Sprangers, David M. Burger, Richard M. W. Hoetelmans, Patricia W. H. Hugen, Sven A. Danner, Marchina E. van der Ende, Margriet M. E. Schneider, Gerrit Schrey, Pieter L. Meenhorst, Herman G. Sprenger, Robert H. Kauffmann, Marielle Jambroes, Margaret A. Chesney, Frank de Wolf, Joep M. A. Lange, and for the ATHENA Project
Arch Intern Med. 2001;161(16):1962-1968.
ABSTRACT | FULL TEXT